All In Biotech

Drug Trial Radar · NCT01134120

A Study in Myeloproliferative Disorders

A Phase 1 Study of LY2784544 in Patients With JAK2 V617F-Positive Myeloproliferative Disorders

Last checked: Nov 19, 2026Latest source record: Apr 17, 2018 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

80

Planned (sponsor's estimate)

Start

Apr 2010

Primary completion

Apr 2014

Study completion Feb 22, 2018

Sponsor

Lead sponsor
Eli Lilly and CompanyEli Lilly (LLY)
Sponsor type
Industry
First posted
May 31, 2010

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to find out the safe dose range of the study drug in patients with myeloproliferative disorders.

Conditions

  • Myeloproliferative Disorders
  • Thrombocythemia, Essential
  • Polycythemia Vera
  • Primary Myelofibrosis

Interventions

  • LY2784544Drug

    LY2784544 will be supplied as a capsule. The study drug will be taken by mouth daily while the patient is on study. In this study, different patients will be treated at different doses of LY2784544 until reaching the highest dose that patients can tolerate.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Determination of a recommended Phase 2 dosing regimenTime frame: Time of first dose until last dose
  2. Number of participants with clinical significant effectsTime frame: Time of first dose until last dose

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

    Houston, Texas

  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

    Salt Lake City, Utah

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.